Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Pilot Study of the Efficacy and Safety of Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

NCT04134182 is registered in ClinicalTrials.gov with Kidney Cancer Research Bureau as lead sponsor.

NCT NCT04134182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Pilot Study of the Efficacy and Safety of Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
Lead sponsor
Kidney Cancer Research Bureau
Phase
Phase 2
Overall status
Unknown status
Start date
October 16, 2019
Completion date
December 31, 2021
Enrollment
8 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma